Pfizer and BioNTech's COVID-19 vaccine demonstrates over 90% efficacy as hope builds for an early end to the pandem… https://t.co/7oajgLXB0B
IHS examines the global experience with risk sharing agreements in recent conference presentation
Last week I presented, with IHS colleague Sarika Pundit, about the global experience with risk sharing agreements at the CBI Reimbursement and Contracting conference in Philadelphia. Among other things, we examined the trends in risk sharing agreements (known as patient access schemes (PAS) in some markets) and the growing prevalence of finance-based agreements. The therapeutic areas most likely to be affected by risk sharing were also reviewed, along with recent regulatory developments that could encourage greater utilisation of risk sharing deals. The analysis was based on the IHS Risk Sharing database and our Payer Partnerships Multi Client study, with additional insights provided from risk sharing coverage in our Same Day Analysis service, Special reports and the IHS International Reference Pricing (IRP) matrix. An abbreviated version of the presentation is available below.
Milena Izmirlieva is the head of the life sciences research team at IHS
Posted 3 March 2015
- Pfizer and BioNTech's COVID-19 vaccine
- Mixed news on COVID19 vaccines: COVID-19 R&D tracker
- Innovation in Japan’s regenerative sector
- US drug prices could be drastically impacted by Most Favored Nation executive order
- Global healthcare spend to remain stable
- The pandemic pricing dilemma: A COVID-19 vaccine at-cost or for profit?
- US school re-opening decisions in a pandemic environment are complex – data can help
- Trump resurrects International Reference Pricing (IRP) proposal on pharmaceuticals with executive order
Register from the latest on the progression of the pandemic and the future that lies ahead of us from our Vice Pres… https://t.co/GiqhM1V318
We are expecting major clinical readouts from several key COVID-19 vaccine and therapeutics candidates- our weekly… https://t.co/aIcNOmccrx